An experimental drug from Vertex Pharmaceuticals helped cure more than 60 percent of patients with a tough-to-treat form of hepatitis C, according to data to be presented at a medical meeting that starts today.
The results, eagerly awaited by Wall Street as well as by doctors, represent the highest cure rate yet reported for the condition — and the treatment was accomplished in half the usual time.
But Vertex might have to share a bit of the limelight with Romark Laboratories, a tiny privately held company that already sells a drug called Alinia that is used to treat diarrhea caused by certain parasites but that suddenly is emerging as a potential treatment for hepatitis C.
http://www.nytimes.com/2007/11/02/business/02drug.html?em&ex=1194325200&en=43e7fb6a5ae22707&ei=5087
The results, eagerly awaited by Wall Street as well as by doctors, represent the highest cure rate yet reported for the condition — and the treatment was accomplished in half the usual time.
But Vertex might have to share a bit of the limelight with Romark Laboratories, a tiny privately held company that already sells a drug called Alinia that is used to treat diarrhea caused by certain parasites but that suddenly is emerging as a potential treatment for hepatitis C.
http://www.nytimes.com/2007/11/02/business/02drug.html?em&ex=1194325200&en=43e7fb6a5ae22707&ei=5087